MiR-182-5p and miR-375-3p Have Higher Performance Than PSA in Discriminating Prostate Cancer from Benign Prostate Hyperplasia
Abstract
:Simple Summary
Abstract
1. Introduction
2. Materials and Methods
2.1. Study Population
2.2. Sample Collection
2.3. MiRNA Analysis
2.4. Statistical Analysis
3. Results
3.1. Patient’s Characteristics
3.2. Blood and Seminal Plasma Expression of miRNAs
3.3. Association of miRNAs with Clinicopathological Variables of PCa Patients
3.4. MiRNAs Co-Expression
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Global Cancer Observatory. Available online: https://gco.iarc.fr/ (accessed on 17 August 2020).
- Draisma, G.; Etzioni, R.; Tsodikov, A.; Mariotto, A.; Wever, E.; Gulati, R.; Feuer, E.; De Koning, H. Lead time and overdiagnosis in prostate-specific antigen screening: Importance of methods and context. J. Natl. Cancer Inst. 2009, 101, 374–383. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- McNally, C.J.; Ruddock, M.W.; Moore, T.; McKenna, D.J. Biomarkers that differentiate benign prostatic hyperplasia from prostate cancer: A literature review. Cancer Manag. Res. 2020, 12, 5225–5241. [Google Scholar] [CrossRef]
- Neuhaus, J.; Yang, B. Liquid Biopsy Potential Biomarkers in Prostate Cancer. Diagnostics 2018, 8, 68. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Esquela-Kerscher, A.; Slack, F.J. Oncomirs-MicroRNAs with a role in cancer. Nat. Rev. Cancer 2006, 6, 259–269. [Google Scholar] [CrossRef] [PubMed]
- Volinia, S.; Calin, G.A.; Liu, C.G.; Ambs, S.; Cimmino, A.; Petrocca, F.; Visone, R.; Iorio, M.; Roldo, C.; Ferracin, M.; et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc. Natl. Acad. Sci. USA 2006, 103, 2257–2261. [Google Scholar] [CrossRef] [Green Version]
- Mitchell, P.S.; Parkin, R.K.; Kroh, E.M.; Fritz, B.R.; Wyman, S.K.; Pogosova-Agadjanyan, E.L.; Peterson, A.; Noteboom, J.; O’Briant, K.C.; Allen, A.; et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. USA 2008, 105, 10513–10518. [Google Scholar] [CrossRef] [Green Version]
- Abramovic, I.; Ulamec, M.; Bojanac Katusic, A.; Bulic-Jakus, F.; Jezek, D.; Sincic, N. MiRNA in prostate cancer: Challenges toward translation. Epigenomics 2020, 12, 543–558. [Google Scholar] [CrossRef] [PubMed]
- Schwarzenbach, H.; Da Silva, A.M.; Calin, G.; Pantel, K. Data normalization strategies for microRNA quantification. Clin. Chem. 2015, 61, 1333–1342. [Google Scholar] [CrossRef] [PubMed]
- Hindson, C.M.; Chevillet, J.R.; Briggs, H.A.; Gallichotte, E.N.; Ruf, I.K.; Hindson, B.J.; Vessella, R.L.; Tewari, M. Absolute quantification by droplet digital PCR versus analog real-time PCR. Nat. Methods 2013, 10, 1003–1005. [Google Scholar] [CrossRef]
- Campomenosi, P.; Gini, E.; Noonan, D.M.; Poli, A.; D’Antona, P.; Rotolo, N.; Dominioni, L.; Imperatori, A. A comparison between quantitative PCR and droplet digital PCR technologies for circulating microRNA quantification in human lung cancer. BMC Biotechnol. 2016, 16, 60. [Google Scholar] [CrossRef] [Green Version]
- Roberts, M.J.; Richards, R.S.; Gardiner, R.A.; Selth, L.A. Seminal fluid: A useful source of prostate cancer biomarkers? Biomark. Med. 2015, 9, 77–80. [Google Scholar] [CrossRef] [PubMed]
- Barceló, M.; Castells, M.; Pérez-Riba, M.; Bassas, L.; Vigués, F.; Larriba, S. Seminal plasma microRNAs improve diagnosis/prognosis of prostate cancer in men with moderately altered prostate-specific antigen. Am. J. Transl. Res. 2020, 12, 2041–2051. [Google Scholar] [PubMed]
- Barceló, M.; Castells, M.; Bassas, L.; Vigués, F.; Larriba, S. Semen miRNAs Contained in Exosomes as Non-Invasive Biomarkers for Prostate Cancer Diagnosis. Sci. Rep. 2019, 9, 13772. [Google Scholar] [CrossRef] [Green Version]
- Roberts, M.J.; Chow, C.W.K.; Schirra, H.J.; Richards, R.; Buck, M.; Selth, L.A.; Doi, S.A.R.; Samaratunga, H.; Perry-Keene, J.; Payton, D.; et al. Diagnostic performance of PCA3, Hepsin and microRNA biomarkers in ejaculate in combination with serum PSA for the detection and triaging of prostate cancer. BJU Int. 2015, 75, 539–549. [Google Scholar] [CrossRef]
- Selth, L.A.; Roberts, M.J.; Chow, C.W.K.; Marshall, V.R.; Doi, S.A.R.; Vincent, A.D.; Butler, L.M.; Lavin, M.F.; Tilley, W.D.; Gardiner, R.A. Human seminal fluid as a source of prostate cancer-specific microRNA biomarkers. Endocr. Relat. Cancer 2014, 21, 17–21. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kline, M.C.; Duewer, D.L. Evaluating Droplet Digital Polymerase Chain Reaction for the Quantification of Human Genomic DNA: Lifting the Traceability Fog. Anal. Chem. 2017, 9, 4648–4654. [Google Scholar] [CrossRef]
- Youden, W.J. Index for rating diagnostic tests. Cancer 1950, 3, 32–35. [Google Scholar] [CrossRef]
- Glinge, C.; Clauss, S.; Boddum, K.; Jabbari, R.; Jabbari, J.; Risgaard, B.; Tomsits, P.; Hildebrand, B.; Kaèaèb, S.; Wakili, R.; et al. Stability of circulating blood-based microRNAs-Pre-Analytic methodological considerations. PLoS ONE 2017, 12, e0167969. [Google Scholar] [CrossRef]
- Matias-Garcia, P.R.; Wilson, R.; Mussack, V.; Reischl, E.; Waldenberger, M.; Gieger, C.; Anton, G.; Peters, A.; Kuehn-Steven, A. Impact of long-term storage and freeze-thawing on eight circulating microRNAs in plasma samples. PLoS ONE 2020, 15, e0227648. [Google Scholar] [CrossRef]
- Faraldi, M.; Sansoni, V.; Perego, S.; Gomarasca, M.; Kortas, J.; Ziemann, E.; Banfi, G.; Lombardi, G. Study of the preanalytical variables affecting the measurement of clinically relevant free-circulating microRNAs: Focus on sample matrix, platelet depletion, and storage conditions. Biochem. Medica 2020, 30, 010703. [Google Scholar] [CrossRef]
- Thompson, I.M.; Ankerst, D.P.; Chi, C.; Lucia, M.S.; Goodman, P.J.; Crowley, J.J.; Parnes, H.L.; Coltman, C.A. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/mL or lower. J. Am. Med. Assoc. 2005, 294, 66–70. [Google Scholar] [CrossRef]
- Bidarra, D.; Constâncio, V.; Barros-Silva, D.; Ramalho-Carvalho, J.; Moreira-Barbosa, C.; Antunes, L.; Maurício, J.; Oliveira, J.; Henrique, R.; Jerónimo, C. Circulating MicroRNAs as Biomarkers for Prostate Cancer Detection and Metastasis Development Prediction. Front. Oncol. 2019, 9, 900. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mitchell, A.J.; Gray, W.D.; Hayek, S.S.; Ko, Y.A.; Thomas, S.; Rooney, K.; Awad, M.; Roback, J.D.; Quyyumi, A.; Searles, C.D. Platelets confound the measurement of extracellular miRNA in archived plasma. Sci. Rep. 2016, 6, 32651. [Google Scholar] [CrossRef] [Green Version]
- Binderup, H.G.; Houlind, K.; Madsen, J.S.; Brasen, C.L. Pre-storage centrifugation conditions have significant impact on measured microRNA levels in biobanked EDTA plasma samples. Biochem. Biophys. Rep. 2016, 7, 195–200. [Google Scholar] [CrossRef] [Green Version]
- Cheng, H.H.; Yi, H.S.; Kim, Y.; Kroh, E.M.; Chien, J.W.; Eaton, K.D.; Goodman, M.T.; Tait, J.F.; Tewari, M.; Pritchard, C.C. Plasma Processing Conditions Substantially Influence Circulating microRNA Biomarker Levels. PLoS ONE 2013, 8, e64795. [Google Scholar] [CrossRef] [Green Version]
- Luu, H.N.; Lin, H.Y.; Sørensen, K.D.; Ogunwobi, O.O.; Kumar, N.; Chornokur, G.; Phelan, C.; Jones, D.; Kidd, L.C.; Batra, J.; et al. miRNAs associated with prostate cancer risk and progression. BMC Urol. 2017, 17, 18. [Google Scholar] [CrossRef] [Green Version]
- Baumann, B.; Acosta, A.M.; Richards, Z.; Deaton, R.; Sapatynska, A.; Murphy, A.; Kajdacsy-Balla, A.; Gann, P.H.; Nonn, L. Association of High miR-182 Levels with Low-Risk Prostate Cancer. Am. J. Pathol. 2019, 189, 911–923. [Google Scholar] [CrossRef] [Green Version]
- Fredsøe, J.; Rasmussen, A.K.I.; Mouritzen, P.; Bjerre, M.T.; Østergren, P.; Fode, M.; Borre, M.; Sørensen, K.D. Profiling of circulating microRNAs in prostate cancer reveals diagnostic biomarker potential. Diagnostics 2020, 10, 188. [Google Scholar] [CrossRef] [Green Version]
- Endzelinš, E.; Berger, A.; Melne, V.; Bajo-Santos, C.; Sobolevska, K.; Abols, A.; Rodriguez, M.; Šantare, D.; Rudnickiha, A.; Lietuvietis, V.; et al. Detection of circulating miRNAs: Comparative analysis of extracellular vesicle-incorporated miRNAs and cell-free miRNAs in whole plasma of prostate cancer patients. BMC Cancer 2017, 17, 730. [Google Scholar] [CrossRef] [PubMed]
- Gao, Y.; Guo, Y.; Wang, Z.; Dai, Z.; Xu, Y.; Zhang, W.; Liu, Z.; Li, S. Analysis of circulating miRNAs 21 and 375 as potential biomarkers for early diagnosis of prostate cancer. Neoplasma 2016, 63, 623–628. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kachakova, D.; Mitkova, A.; Popov, E.; Popov, I.; Vlahova, A.; Dikov, T.; Christova, S.; Mitev, V.; Slavov, C.; Kaneva, R. Combinations of Serum Prostate-Specific Antigen and Plasma Expression Levels of let-7c, miR-30c, miR-141, and miR-375 as Potential Better Diagnostic Biomarkers for Prostate Cancer. DNA Cell Biol. 2014, 34, 189–200. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mishra, S.; Deng, J.J.; Gowda, P.S.; Rao, M.K.; Lin, C.L.; Chen, C.L.; Huang, T.; Sun, L.Z. Androgen receptor and microRNA-21 axis downregulates transforming growth factor beta receptor II (TGFBR2) expression in prostate cancer. Oncogene 2014, 33, 4091–4106. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Egevad, L.; Delahunt, B.; Srigley, J.R.; Samaratunga, H. International Society of Urological Pathology (ISUP) grading of prostate cancer-An ISUP consensus on contemporary grading. APMIS 2016, 124, 433–435. [Google Scholar] [CrossRef]
- Pastor-Navarro, B.; García-Flores, M.; Fernández-Serra, A.; Blanch-Tormo, S.; de Juan, F.M.; Martínez-Lapiedra, C.; de Alcantara, F.M.; Peñalver, J.C.; Cervera-Deval, J.; Rubio-Briones, J.; et al. A tetra-panel of serum circulating mirnas for the diagnosis of the four most prevalent tumor types. Int. J. Mol. Sci. 2020, 21, 2783. [Google Scholar] [CrossRef] [Green Version]
- Dybos, S.A.; Flatberg, A.; Halgunset, J.; Viset, T.; Rolfseng, T.; Kvam, S.; Skogseth, H. Increased levels of serum miR-148a-3p are associated with prostate cancer. Apmis 2018, 126, 722–731. [Google Scholar] [CrossRef]
- Al-Qatati, A.; Akrong, C.; Stevic, I.; Pantel, K.; Awe, J.; Saranchuk, J.; Drachenberg, D.; Mai, S.; Schwarzenbach, H. Plasma microRNA signature is associated with risk stratification in prostate cancer patients. Int. J. Cancer 2017, 141, 1231–1239. [Google Scholar] [CrossRef] [Green Version]
- Paunescu, I.A.; Bardan, R.; Marcu, A.; Nitusca, D.; Dema, A.; Negru, S.; Balacescu, O.; Balacescu, L.; Cumpanas, A.; Sirbu, I.O.; et al. Biomarker Potential of Plasma MicroRNA-150-5p in Prostate Cancer. Medicina 2019, 55, 564. [Google Scholar] [CrossRef] [Green Version]
- Gurbuz, V.; Kiliccioglu, I.; Ugras Dikmen, A.; Bilen, C.Y.; Sozen, S.; Konac, E. Comparative analysis of epi-miRNA expression levels in local/locally advanced and metastatic prostate cancer patients. Gene 2020, 758, 144963. [Google Scholar] [CrossRef]
- Lo, U.G.; Yang, D.; Hsieh, J.T. The role of microRNAs in prostate cancer progression. Transl. Androl. Urol. 2013, 2, 228–241. [Google Scholar] [CrossRef]
- Ponti, G.; Manfredini, M.; Tomasi, A. Non-blood sources of cell-free DNA for cancer molecular profiling in clinical pathology and oncology. Crit. Rev. Oncol. Hematol. 2019, 141, 36–42. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zedan, A.H.; Osther, P.J.S.; Assenholt, J.; Madsen, J.S.; Hansen, T.F. Circulating miR-141 and miR-375 are associated with treatment outcome in metastatic castration resistant prostate cancer. Sci. Rep. 2020, 10, 227. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yao, J.; Xu, C.; Fang, Z.; Li, Y.; Liu, H.; Wang, Y.; Xu, C.; Sun, Y. Androgen receptor regulated microRNA miR-182-5p promotes prostate cancer progression by targeting the ARRDC3/ITGB4 pathway. Biochem. Biophys. Res. Commun. 2016, 474, 213–219. [Google Scholar] [CrossRef] [PubMed]
- Wang, D.; Lu, G.; Shao, Y.; Xu, D. MiR-182 promotes prostate cancer progression through activating Wnt/β-catenin signal pathway. Biomed. Pharmacother. 2018, 99, 334–339. [Google Scholar] [CrossRef] [PubMed]
- Cui, C.; Cui, Q. The relationship of human tissue microRNAs with those from body fluids. Sci. Rep. 2020, 10, 5644. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Clinicopathological Variables | PCa (n = 65) | BPH (n = 58) |
---|---|---|
median age, years (range) | 65 (40–92) | 63 (47–78) |
pre-biopsy PSA median, µg/L (n; 25–75 percentile) | 7.10 (64; 5.53–10.67) | 7.82 (58; 5.48–10.14) |
pre-biopsy PSA levels, n (%) | ||
≤10 µg/L | 46 (70.8%) | 42 (72.4%) |
>10 µg/L | 18 (27.7%) | 16 (27.6%) |
unknown | 1 (1.5%) | 0 (0%) |
GS, n (%) | ||
6 | 19 (29.2%) | n.a. |
7 | 40 (61.5%) | n.a. |
8 | 4 (6.2%) | n.a. |
9 | 2 (3.1%) | n.a. |
WHO 2016/ISUP grade | ||
1 (GS 3 + 3 = 6) | 19 (29.2%) | n.a. |
2 (GS 3 + 4 = 7) | 30 (46.1%) | n.a. |
3 (GS 4 + 3 = 7) | 10 (15.4%) | n.a. |
4 (GS 4 + 4, 3 + 5 or 5+3 = 8) | 4 (6.2%) | n.a. |
5 (GS 9 or 10) | 2 (3.1%) | n.a. |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Abramovic, I.; Vrhovec, B.; Skara, L.; Vrtaric, A.; Nikolac Gabaj, N.; Kulis, T.; Stimac, G.; Ljiljak, D.; Ruzic, B.; Kastelan, Z.; et al. MiR-182-5p and miR-375-3p Have Higher Performance Than PSA in Discriminating Prostate Cancer from Benign Prostate Hyperplasia. Cancers 2021, 13, 2068. https://doi.org/10.3390/cancers13092068
Abramovic I, Vrhovec B, Skara L, Vrtaric A, Nikolac Gabaj N, Kulis T, Stimac G, Ljiljak D, Ruzic B, Kastelan Z, et al. MiR-182-5p and miR-375-3p Have Higher Performance Than PSA in Discriminating Prostate Cancer from Benign Prostate Hyperplasia. Cancers. 2021; 13(9):2068. https://doi.org/10.3390/cancers13092068
Chicago/Turabian StyleAbramovic, Irena, Borna Vrhovec, Lucija Skara, Alen Vrtaric, Nora Nikolac Gabaj, Tomislav Kulis, Goran Stimac, Dejan Ljiljak, Boris Ruzic, Zeljko Kastelan, and et al. 2021. "MiR-182-5p and miR-375-3p Have Higher Performance Than PSA in Discriminating Prostate Cancer from Benign Prostate Hyperplasia" Cancers 13, no. 9: 2068. https://doi.org/10.3390/cancers13092068